An event organized by OPALE, The Organization for Partnerships in Leukemia, and supported by France's National Cancer Institute
Conference center
Pierre Mendès France
139, rue de Bercy,
75012 Paris
THE PREMIER PLACE FOR PUBLIC-PRIVATE PARTNERSHIPS IN LEUKEMIA
Pr Hervé Dombret
OPALE’s Chairman
Corporate Social Responsibility (CSR)
The organizers, sensitive to gender parity in the field of research and more generally in society, have ensured that the gender of speakers and chairs approaches gender parity.
The OPALE Association, organizer of LEUKEMIA 360 on behalf of the OPALE Carnot Institute, is a signatory of the Diversity Charter, and respects its principles in the management of its human resources, particularly in the context of this event.
We have chosen an intramural venue easily accessible by all means of transport, to avoid delegates having to travel by car.
A dedicated application will enable delegates to exchange virtual business cards.
Invitation to LEUKEMIA 360 – Paris, November 13, 2025
Accelerating Innovation Together in Leukemia and Related Diseases.
Dear colleagues and innovation stakeholders,
After a successful launch last year, we are pleased to invite you to the 2nd edition of LEUKEMIA 360, a major event taking place on November 13, 2025, in Paris, aimed at becoming the premier international meeting devoted to academia-industry leukemia R&D&I partnerships.
This unique forum will bring together academic experts (researchers, clinicians, and operational staff from 75 research teams), industry leaders and specialists, innovators, investors, and patient representatives, working in the field of leukemia and related diseases. The goal : to foster connections, stimulate collaborative R&D, and build strategic partnerships across the entire value chain — from the identification of novel therapeutic targets to industrial development.
In the face of ongoing unmet medical and industrial needs, LEUKEMIA 360, organized by OPALE Carnot Institute, The Organization for Partnerships in Leukemia, serves as a catalyst to accelerate innovation, together, and save more lives of adult and pediatric patients suffering of AML, ALL, MDS, MPN and other rare related disorders.
What to expect:
🔬 Cutting-edge scientific presentations
🚀Highlights of companies active in the leukemia field
🤝 Networking sessions and 1:1 meetings
🧑🏻🔬 R&D workshops with matter experts presenting their platforms
🌍 A collaborative perspective to connect the ecosystem’s players
Join us in Paris for the 2025 edition of LEUKEMIA 360 and be part of this collective momentum shaping tomorrow’s breakthroughs and accelerating therapeutic and diagnostic innovation in the field of leukemia and related diseases!
An event by
and supported by France’s National Cancer Institute